Navigation Links
Iomai Announces Data from Phase 2 Field Study of Travelers' Diarrhea Vaccine Accepted for Presentation at ICAAC
Date:8/23/2007

GAITHERSBURG, Md., Aug. 23 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced that the abstract detailing efficacy and safety results from its double-blind Phase 2 field study of a patch-based vaccine for travelers' diarrhea has been accepted as a "late breaker" presentation at Interscience Conference on Antimicrobials and Chemotherapy (ICAAC), to be held in Chicago Sept. 17 to 20.

The abstract, "Transcutaneous Immunization with the Heat Labile Toxin (LT) of Enterotoxigenic Escherichia coli (ETEC) Protects in a Phase 2 Field Trial in Travelers to Guatemala and Mexico," will be presented by Gregory Glenn, M.D., Iomai's chief scientific officer, on Tuesday, Sept. 18, during the session on "Vaccines and Pediatric Infections." The session will be held from 1:30 to 4 p.m.

About Travelers' Diarrhea

This year, approximately 55 million international travelers will visit countries where bacteria that cause travelers' diarrhea are endemic, particularly Africa, Asia and Latin America, and about 20 million of those travelers will develop travelers' diarrhea.

Travelers' diarrhea (TD) is caused by ingestion of pathogens in contaminated food and water. Of the 54 million travelers to endemic areas, an estimated 17 million will contract TD, making it one of the most common illnesses in travelers. Symptoms last for 3 to 5 days, and 55 percent of subjects who become ill have more than six stools daily, with an average of 18 total stools per episode. TD is often accompanied by nausea, vomiting and cramping and can result in severe dehydration, mimicking the symptoms of cholera. Although generally self-limited, TD is often accompanied by prostration and can require hospitalization, often in settings where health care is inadequate. Additionally, 10 to 30 percent of travelers who contract diarrhea also develop a more chronic condition, irritable bowel syndrome.

About Iomai Corporation

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.


'/>"/>
SOURCE Iomai Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Iomai to Announce Results From Phase 1 Influenza Trial and Host Webcast Tomorrow
2. Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers Diarrhea Stimulates Immune Response Even at Low Doses
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... , May 4, 2017  A recent study ... Ultraviolet-C light as a means of ... ability to reduce bioburden on anesthesia workstations. In ... on high-touch, complex medical equipment surfaces contaminated with ... "This study further validates the body ...
(Date:5/4/2017)... WAYNE, Pa. , May 4, 2017 /PRNewswire/ ... made from thermoplastics and other highly-engineered materials, is ... Microextrusion tubing has been developed in recent ... neurovascular interventional therapies and surgical applications. More expensive ... used to produce microextrusion tubing due to their ...
(Date:5/3/2017)... May 3, 2017  Getinge, a leading global ... quality enhancement and cost efficiency within healthcare and ... of contemporary practice demonstrating that intra-aortic balloon counterpulsation ... critically ill patients. The single-center, retrospective, observational study ... volume MEGA ® 50cc intra-aortic balloon (IAB) ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with ... every IT system, from the datacenter to the cloud to the edge. Through ...
(Date:5/24/2017)... ... 24, 2017 , ... Fiberstar, Inc., http://www.FiberstarIngredients.com a ... beverage industry offers Citri-Fi®, a natural citrus fiber, to improve beverage ingredient declarations. ... a result, labels need to deliver simple, transparent and clear messaging. Listed food ...
(Date:5/23/2017)... ... , ... Allegheny Health Network and the Alexis Joy D’Achille ... Behavioral Health at West Penn Hospital , a unique facility that will offer ... depression. Construction of the Center is underway with a scheduled opening in the ...
(Date:5/23/2017)... ... 2017 , ... The National Council on Strength and Fitness ... organization’s Certified Strength Coach credential has earned accreditation from the National Commission for ... competency of qualified candidates for jobs in the Strength and Conditioning profession. The ...
(Date:5/23/2017)... New York (PRWEB) , ... May 23, 2017 ... ... NextGen LifeLabs, a leading equipment provider in the modern ART laboratory, to provide ... Institute in Ft. Lauderdale, Florida. , NextGen LifeLabs, a MedTech Group Purchasing ...
Breaking Medicine News(10 mins):